The Dr. Hyman Show

Ozempic: A Weight Loss Miracle or Metabolic Menace? A Discussion with Dr. Tyna Moore & Calley Means

36 snips
Apr 17, 2024
Dr. Tyna Moore, a holistic expert in regenerative medicine, and Calley Means, founder of TrueMed, delve into the complexities surrounding GLP-1 agonists like Ozempic. They scrutinize the rising trend of using Ozempic for weight loss and examine the concerning idea of prescribing it to children. The discussion emphasizes the need for lifestyle changes over quick fixes offered by pharmaceuticals. They advocate for a more nuanced approach to metabolic health that integrates personal experiences and systemic healthcare flaws.
Ask episode
AI Snips
Chapters
Books
Transcript
Episode notes
INSIGHT

Medicalization of Chronic Diseases

  • The medicalization of chronic diseases has been a failure, focusing on symptoms instead of root causes.
  • This approach has led to a reliance on medication rather than addressing underlying lifestyle issues.
INSIGHT

Ozempic Pricing and Usage in Denmark

  • Ozempic, a weight-loss drug, is significantly cheaper in Denmark and not standard care for obesity there.
  • Denmark subsidizes exercise and keto diets for obesity; Ozempic profits largely come from the US.
ADVICE

Addressing GLP-1 Deficiency

  • Consider GLP-1 deficiency as a potential factor in appetite dysregulation and obesity.
  • Explore underlying causes like epigenetics, microbiome changes, and environmental toxins.
Get the Snipd Podcast app to discover more snips from this episode
Get the app